% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Baumeister:280047,
author = {Baumeister, Hannah and Gellersen, Helena M and Polk, Sarah
E and Lattmann, René and Wuestefeld, Anika and Wisse, Laura
E M and Glenn, Trevor and Yakupov, Renat and Stark, Melina
and Kleineidam, Luca and Roeske, Sandra and Marcos Morgado,
Barbara and Esselmann, Hermann and Brosseron, Frederic and
Ramirez, Alfredo and Lüsebrink, Falk and Synofzik, Matthis
and Schott, Björn H and Schmid, Matthias C and Hetzer,
Stefan and Dechent, Peter and Scheffler, Klaus and Ewers,
Michael and Hellmann-Regen, Julian and Ersözlü, Ersin and
Spruth, Eike Jakob and Gemenetzi, Maria and Fliessbach,
Klaus and Bartels, Claudia and Rostamzadeh, Ayda and Glanz,
Wenzel and Incesoy, Enise I and Janowitz, Daniel and
Rauchmann, Boris Stephan and Kilimann, Ingo and Sodenkamp,
Sebastian and Coenjaerts, Marie and Spottke, Annika and
Peters, Oliver and Priller, Josef and Schneider, Anja and
Wiltfang, Jens and Buerger, Katharina and Perneczky, Robert
and Teipel, Stefan and Laske, Christoph and Wagner, Michael
and Ziegler, Gabriel and Jessen, Frank and Düzel, Emrah and
Berron, David},
collaboration = {group, DELCODE study},
title = {{D}isease stage-specific atrophy markers in {A}lzheimer's
disease.},
journal = {Alzheimer's and dementia},
volume = {21},
number = {7},
issn = {1552-5260},
address = {Hoboken, NJ},
publisher = {Wiley},
reportid = {DZNE-2025-00886},
pages = {e70482},
year = {2025},
abstract = {Structural magnetic resonance imaging (MRI) often lacks
diagnostic, prognostic, and monitoring value in Alzheimer's
disease (AD), particularly in early disease stages. To
improve its utility, we aimed to identify optimal atrophy
markers for different intended uses.We included 363 older
adults; cognitively unimpaired individuals who were negative
or positive for amyloid beta (Aβ) and Aβ-positive patients
with subjective cognitive decline, mild cognitive
impairment, or dementia of the Alzheimer type. MRI and
neuropsychological assessments were administered annually
for up to 3 years.Accelerated atrophy of medial temporal
lobe subregions was evident already during preclinical AD.
Symptomatic disease stages most notably differed in their
hippocampal and parietal atrophy signatures.
Atrophy-cognition relationships varied by intended use and
disease stage.With the appropriate marker, MRI can detect
abnormal atrophy already during preclinical AD. To optimize
performance, atrophy markers should be tailored to the
targeted disease stage and intended use.Subregional atrophy
markers detect ongoing atrophy in preclinical Alzheimer's
disease (AD). Subjective cognitive decline in preclinical AD
links to manifest atrophy. Optimal atrophy markers differ by
the disease stage and intended use.},
keywords = {Humans / Alzheimer Disease: pathology / Alzheimer Disease:
diagnostic imaging / Atrophy: pathology / Magnetic Resonance
Imaging / Male / Female / Aged / Cognitive Dysfunction:
pathology / Cognitive Dysfunction: diagnostic imaging /
Neuropsychological Tests / Biomarkers / Amyloid
beta-Peptides / Brain: pathology / Brain: diagnostic imaging
/ Disease Progression / Aged, 80 and over / Hippocampus:
pathology / imaging biomarker (Other) / longitudinal atrophy
(Other) / magnetic resonance imaging (Other) / medial
temporal lobe (Other) / parietal lobe (Other) / Biomarkers
(NLM Chemicals) / Amyloid beta-Peptides (NLM Chemicals)},
cin = {AG Berron / AG Düzel / AG Wagner / AG Heneka / Patient
Studies (Bonn) / AG Gasser / AG Fischer / AG Schmid Bonn /
AG Endres / AG Dirnagl / AG Teipel / ICRU / AG Spottke /
Clinical Research Platform (CRP) / AG Peters / AG Priller /
AG Schneider / AG Wiltfang / Clinical Research (Munich) / AG
Dichgans / AG Jessen},
ddc = {610},
cid = {I:(DE-2719)5000070 / I:(DE-2719)5000006 /
I:(DE-2719)1011201 / I:(DE-2719)1011303 / I:(DE-2719)1011101
/ I:(DE-2719)1210000 / I:(DE-2719)1410002 /
I:(DE-2719)1013028 / I:(DE-2719)1811005 / I:(DE-2719)1810002
/ I:(DE-2719)1510100 / I:(DE-2719)1240005 /
I:(DE-2719)1011103 / I:(DE-2719)1011401 / I:(DE-2719)5000000
/ I:(DE-2719)5000007 / I:(DE-2719)1011305 /
I:(DE-2719)1410006 / I:(DE-2719)1111015 / I:(DE-2719)5000022
/ I:(DE-2719)1011102},
pnm = {353 - Clinical and Health Care Research (POF4-353) / 352 -
Disease Mechanisms (POF4-352)},
pid = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352},
experiment = {EXP:(DE-2719)DELCODE-20140101},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40691867},
doi = {10.1002/alz.70482},
url = {https://pub.dzne.de/record/280047},
}